Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis. [PDF]
BMC Pulm Med, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Hu D +6 more
europepmc +2 more sources
Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case-Control Study. [PDF]
J Am Heart AssocBackground Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Chen YC +4 more
europepmc +2 more sources
An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis
Scientific Reports, 2023 Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar +5 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2021 Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced
HUANG Shifen, LING Xiaoling
doaj +1 more source
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review. [PDF]
PLoS ONE, 2016 Currently, the standard treatment for newly diagnosed glioblastoma multiforme (GBM) is maximal safe surgical resection followed by radiation therapy with concurrent and adjuvant temozolomide.
Yawei Wang +4 more
doaj +1 more source
Oftalʹmologiâ, 2014 Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea ...
V. G. Likhvantseva +8 more
doaj +3 more sources
Normal Wound Healing and Tumor Angiogenesis as a Game of Competitive Inhibition. [PDF]
PLoS ONE, 2016 Both normal wound healing and tumor angiogenesis are mitigated by the sequential, carefully orchestrated release of growth stimulators and inhibitors.
Irina Kareva +4 more
doaj +1 more source
Computational modelling of angiogenesis: The importance of cell rearrangements during vascular growth [PDF]
WIREs Mechanisms of Disease, e1634 (2023), 2023 Angiogenesis is the process wherein endothelial cells (ECs) form sprouts that elongate from the pre-existing vasculature to create new vascular networks. In addition to its essential role in normal development, angiogenesis plays a vital role in pathologies such as cancer, diabetes and atherosclerosis.
arxiv +1 more source
Advances in Cancer Research, 2020 The hypothesis that tumors are angiogenesis dependent has, in the past decade, generated new investigations designed to elucidate the mechanism of angiogenesis itself. Many laboratories are now engaged in this pursuit. Some are studying angiogenesis that
Farah Fatmawati, Whendy Wijaksono
semanticscholar +1 more source
Pharmaceuticals, 2010 Angiogenesis is regulated by the local balance between angiogenesis stimulators and inhibitors. A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature.
Yasufumi Sato
doaj +1 more source